Overview

Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study was designed as a single-center, open, non-randomized trial.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Nuokangda Pharmaceutical Technology Co., Ltd.
Treatments:
Norcantharidin